Anonymous wrote:Your doctor is absolutely correct that there are no studies that show any effect one way or the other for Paxlovid on long covid.

Point for that doctor!

Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients – A Large-Scale Observational Cohort Study from the RECOVER Initiative
https://pmc.ncbi.nlm.nih.gov/articles/PMC11213188/
...
Paxlovid treatment was associated with a lower risk of incident Long COVID across systems as shown in Fig. 2D, including post-acute neurological conditions (sleep disorders, cognitive problems, headache, encephalopathy, dementia), post-acute pulmonary conditions (pulmonary fibrosis, acute pharyngitis, shortness of breath), post-acute blood conditions (anemia), post-acute metabolic conditions (edema, diabetes, malnutrition), post-acute digestive conditions (abdominal pain, constipation), post-acute musculoskeletal conditions (joint pain), and some general conditions in the post-acute phase (e.g., malaise and fatigue, fever, smell, and taste).
...
Paxlovid treatment was also associated with a lower risk of incident Long COVID in different subpopulations stratified by sex, race, age, baseline risk conditions (except for pregnant females), infection time, and different rural-urban commuting areas as shown in Fig. 3.

Paxlovid tied to fewer COVID-19 hospitalizations, reduced risk of long COVID
https://www.cidrap.umn.edu/covid-19/paxlovid-tied-fewer-covid-19-hospitalizations-reduced-risk-long-covid

A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.

Long COVID: What have we learned?
https://health.ucdavis.edu/news/headlines/long-covid-what-have-we-learned/2024/10

Most importantly, we have learned that both vaccination and treatment with Paxlovid reduces the likelihood of long COVID.